Clinical Trial: CP-MGC018-01

Trial Status: Open
Trial Type: Solid Tumors
Disease Type: Solid Tumors All
Trial ID CP-MGC018-01
Sponsor ID CP-MGC018-01

A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of MGC018 (Anti–B7-H3 Antibody Drug Conjugate) Alone and in Combination with MGA012 (Anti–PD-1 Antibody) in Patients with Advanced Solid Tumors

Locations

Fairfax Office

Learn More About This Trial

Other Relevant Trials
Trial ID 516-014
Sponsor ID Mirati

A Multicenter, Open-Label, Extension Study of the Safety and Tolerability of Sitravatinib Alone or in Combination with Other Anticancer Therapies in Patients with Advanced or Metastatic Solid Malignancies

Trial ID JBI-802-101
Sponsor ID Jubilant Therapeutics

A First-in-Human, Open-Label, Dose Escalation and Expansion Study of Orally Administered JBI-802 in Patients with Advanced Solid Tumors